
Neurocrine Biosciences NBIX
$ 120.39
3.69%
Annual report 2024
added 02-10-2025
Country |
![]() |
IPO year |
1996 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
CEO |
Dr. Kevin Gorman |
Employees in the company |
825 |
Shares |
100 M |
Market Cap[1] |
$ 12.1 B |
EBITDA (LTM) |
$ 148 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.